|1.||Tillequin, F: 6 articles (09/2009 - 06/2000)|
|2.||Michel, S: 5 articles (09/2009 - 06/2000)|
|3.||Koch, M: 5 articles (01/2005 - 06/2000)|
|4.||Atassi, G: 5 articles (12/2001 - 06/2000)|
|5.||Pierré, Alain: 4 articles (12/2005 - 04/2002)|
|6.||Pfeiffer, B: 4 articles (12/2001 - 06/2000)|
|7.||Pierré, A: 4 articles (12/2001 - 06/2000)|
|8.||Koch, Michel: 3 articles (01/2007 - 03/2004)|
|9.||Léonce, Stéphane: 3 articles (03/2004 - 04/2002)|
|10.||Michel, Sylvie: 3 articles (03/2004 - 09/2002)|
09/01/2009 - "The pyranoacridone acronycine (1) exhibits antitumor properties against a large panel of solid tumor models, but its moderate potency and low water solubility severely hampered the subsequent clinical trials. "
03/01/2004 - "Acronycine has been tested against human cancers in the early 1980s, but the clinical trials showed modest therapeutic effects and its development was rapidly discontinued. "
01/01/2015 - "S23906 is an acronycine derivative that shows strong activity toward solid tumors in experimental models. "
09/01/2002 - "Acronycine is active against a broad spectrum of solid tumors. "
08/01/2001 - "Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors."
12/01/2005 - "Cyclization gave the corresponding naphtho[1,2-b][1,10]-phenanthrolin-7(14H)-ones 29 and 30, and naphtho[1,2-b][1,7]-phenanthrolin-7(14H)-one 31, which were subsequently N-methylated to the desired 14-methylnaphtho[1,2-b][1,10] and [1,7]-phenanthrolinones 6, 7, and 8. Benzo[c]pyrano[3,2-h]acridin-7-one derivatives 3, 16, and 22 displayed cytotoxic activities within the same range of magnitude as acronycine itself, whereas 7-alkoxybenzo[c]pyrano[3,2-h]acridine and 7-acyloxybenzo[c]pyrano[3,2-h]acridine derivatives 4 and 17-21 were less active when tested against L1210 murine leukemia cells in vitro. "
06/01/2001 - "cis-3,4-Diacetoxy-5-methoxy-2,2-dimethyl-3,4-dihydro-2H,6H-benzo[b]pyrano[2,3-i]xanthen-6-one, the most active among the new compounds, was more potent than acronycine in inhibiting the proliferation of L1210 murine leukemia cells."
02/01/1998 - "Diacetate 12 was evaluated in vivo against murine P-388 leukemia and was markedly active at a dose 16-fold lower than acronycine itself. "
06/01/1977 - "Effects of acronycine on cell-surface properties of murine leukemia cells."
01/01/1981 - "Effects of acronycine and of cytochalasin B on the division of rat leukemia cells."
|3.||Colonic Neoplasms (Colon Cancer)
07/01/2002 - "In vivo, cis-1,2-diacetoxy-1,2-dihydrobenzo[b] acronycine (S 23906-1), selected for further preclinical development, demonstrated a marked antitumor activity in human orthotopic models of lung, ovarian and colon cancers xenografted in nude mice."
01/01/2005 - "In vivo, cis-1.2-diacetoxy-1,2-dihydrobenzo[b]acronycine, selected for further development under the code S 23906-1, demonstated a marked antitumor activity in human orthotopic models of lung, ovarian and colon cancers xenografted in nude mice. "
01/01/2005 - "In vivo, 1,2-dihydroxy-1,2-dihydrobenzo[b]acronycine esters and diesters, exemplified by cis-1,2-diacetoxy-1,2-dihydrobenzo[b]acronycine developed under the code S 23906-1, demonstated a marked antitumor activity in human orthotopic models of lung, ovarian and colon cancers xenografted in nude mice. "
12/01/2001 - "Using a clonogenic assay of cell survival, the HT29 human colon carcinoma cell line was 100-fold more sensitive to S23906-1 than acronycine. "
01/01/1986 - "The standard chemotherapeutic agents carmusine (BCNU), cis-platinum, mitomycin-C, and vinblastine as well as the investigational agents mitoxantrone, acronycine, acivicin, and methylglyoxalbisguanylhydrazone (MGBG) demonstrated some in vitro activity and could be useful in carcinoma of the gallbladder and biliary tree. "
|6.||Vinblastine (Vinblastine Sulfate)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)